So far, no drug has received the Food and Drug Administration (FDA) or European Medicines Agency (EMA) authorization for treating HHT associated manifestations, but ongoing investigations are actively engaged to find novel therapeutic targets within signaling pathways where endoglin is involved [37, 80, 82]. Here, ENG is linked to hereditary hemorrhagic telangiectasia.